Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in prophylaxis and treatment of bleeds in previously N8-GP treated patients with severe haemophilia A
2017-003788-36Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of adverse events reported. Started Jan 2018; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2017-003788-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003788-36.